salarius pharmaceuticals inc 2025年季度报告

Quantitative and Qualitative Disclosures about Market RiskControls and Procedures Various statements made in this Quarterly Report on Form 10-Q are forward-looking and involve risks and uncertainties.All statements that address activities, events or developments that we intend, expect or believe may occur in the futureare forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section21E of the Securities Exchange Act of 1934, as amended. Such statements give our current expectations or forecasts of our ability to continue as a going concern and support our operations into the later part of the second quarter ofour expectations regarding the timing, likelihood, expected benefits of, and potential value created by, the proposed merger (the “Merger”) between us and Decoy Therapeutics Inc. (“Decoy”);our expectations regarding the satisfaction of certain conditions to the completion of the Merger, including the million (the “Qualified Financing”), whether and when the Merger will be consummated and that our common stockremains listed on Nasdaq; stockholders in the combined company;our expectations regarding our clinical trials and any investigator-initiated clinical trials;our expectations as to revenue, cash flow, and expenses;our liquidity position, the expected sufficiency of such position for anticipated operating and capital requirements; Forward-looking statements also include statements other than statements of current or historical fact, including, withoutlimitation, all statementsrelated to any expectations of revenues, expenses, cash flows, earnings or losses fromoperations, cash required to maintain current and planned operations, capital or other financial items; any statements ofthe plans, strategies and objectives of management for future operations; any plans or expectations with respect toproductresearch,development and commercialization,including regulatory approvals;any other statements of The following are some of the factors that could cause actual results to differ materially from the anticipated results orother expectations expressed, anticipated or implied in our forward-looking statements: the Merger or obtain additional financing in the near term, the company will need to pursue a dissolution andliquidation of our company; the risk that our stockholders may not realize a benefit from the Merger commensurate with the ownership dilutionthey will experience in connection with the Merger and the Qualified Financing; the Merger consideration may have greater or lesser value at the closing of the Merger than at the time themerger agreement was signed;failure to complete the Merger may result in Salarius paying a termination fee or expenses to Decoy and couldharm the financial condition and operations of Salarius;if the conditions to the Merger are not met, including failure to consummate a Qualified Financing, or failure to comply with the continued listing standards of Nasdaq, the Merger may not occur;the timing of the consummation of the Merger is uncertain as is the ability of each of Salarius and Decoy toconsummate the Merger;the Merger may be completed even though material adverse changes may occur; Salarius may not be able to maintain its Nasdaq listing following the Merger Closing;as a result of any adjustments in the exchange ratio and Qualified Financing, Salarius’ stockholders may own less of the combined company than is currently anticipated;the market price of Salarius’ common stock may decline following the Merger;restrictions in the Merger Agreement may prevent Salarius from entering into a business combination with anotherparty at a favorable price;certain provisions of the Merger Agreement may discourage third parties from submitting alternative takeoverproposals, including proposals that may be superior to the arrangements contemplated by the Merger Agreement;the risk that the Merger, even if it is consummated, may not enhance stockholder value and may create adistraction or uncertainty that may adversely affect our operating results, business or investor perceptions;the combined company may not be able to raise additional funds when necessary, and/or on acceptable terms;potential adverse impacts regarding our continued implementation of cost-savings measures designed to extendour expected cash runway;the risk that the Company’s cost saving initiatives and exploration of strategic alternatives are not successful anddo not increase stockholder value;unanticipated difficulties with preserving capital;unanticipated charges not currently contemplated that may occur as a result of the Company’s cost savings plan;uncertainties about the paths of our programs and our ability to evaluate and identify a path forward for those Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligationto publicly update or revise our forward-looking statements even if experience or